Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FDB

TAGS

Novavax has signed an agreement with FUJIFILM Diosynth Biotechnologies (FDB), a US-based contract development and manufacturing organization (CDMO), for the manufacturing of bulk drug substance for NVX-CoV2373, the former’s COVID-19 vaccine candidate.

FUJIFILM Diosynth Biotechnologies’ facility in Morrisville, North Carolina has started production of the first batch of NVX-CoV2373.

The arrangement between the two firms comes under the recent $1.6 billion order bagged by Novavax from the US government as part of Operation Warp Speed program, which is targeting to start delivering millions of doses of a safe, effective vaccine for COVID-19 to the American public.

See also  Nova Marketing Services and Nova Brand Projection merge to form branding powerhouse

Novavax said that it is using the funding from Operation Warp Speed program for completing late-stage clinical development, which includes a phase 3 clinical trial, apart from setting up large-scale manufacturing, and for supplying 100 million doses of NVX–CoV2373 beginning as early as late 2020.

Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FUJIFILM Diosynth Biotechnologies

Novavax NVX-CoV2373 COVID-19 vaccine candidate to be manufactured by FUJIFILM Diosynth Biotechnologies

Stanley C. Erck – President and CEO of Novavax said: “We are grateful to partner with the team at FUJIFILM Diosynth Biotechnologies to ensure the large-scale manufacture of our COVID-19 vaccine candidate.

See also  Ferring Pharmaceuticals begins treatment of first US patient with ADSTILADRIN

“We are committed to working together with unprecedented speed to deliver a vaccine to protect our nation’s population.”

According to the US vaccine development company, NVX-CoV2373 contains a stable, prefusion protein, which is made by using the company’s nanoparticle technology besides including its Matrix–M adjuvant.

Novavax said that the batches of the COVID-19 vaccine candidate produced at the FUJIFILM Diosynth Biotechnologies site in North Carolina will be used in a future phase 3 clinical trial of up to 30,000 subjects which is anticipated to start in the fall of 2020. The phase 3 trial will evaluate the safety and efficacy of the NVX-CoV2373 against the SARS-CoV-2 coronavirus.

See also  Jardine Lloyd Thompson to be acquired by Marsh & McLennan in $5.6bn deal

Martin Meeson – CEO of FUJIFILM Diosynth Biotechnologies said: “We are delighted to bring our leading technical expertise in baculovirus systems and our proven manufacturing excellence to support Novavax’ response to this global crisis.

“As a critical partner to Novavax, our focus is to advance the delivery of a vaccine that can have a profound impact.”

CATEGORIES
TAGS
Share This